Edition:
India

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

16.44EUR
18 May 2018
Change (% chg)

€0.09 (+0.55%)
Prev Close
€16.35
Open
€16.52
Day's High
€16.71
Day's Low
€16.17
Volume
59,826
Avg. Vol
296,195
52-wk High
€19.42
52-wk Low
€8.53

Chart for

About

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modi... (more)

Overall

Beta: 1.27
Market Cap(Mil.): €287.57
Shares Outstanding(Mil.): 22.30
Dividend: --
Yield (%): --

Financials

German stocks - Factors to watch on May 15

BERLIN/FRANKFURT, May 15 The following are some of the factors that may move German stocks on Tuesday:

15 May 2018

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

14 May 2018

UPDATE 1-Medigene in for up to $1.5 bln under broader pact with Bluebird Bio

* Shares up 8 pct (Adds shares, background on technology, analyst comment)

14 May 2018

Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT, May 14 German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

14 May 2018

BRIEF-Medigene AG Medigene Appoints Dr. Kai Pinkernell To Executive Management Board As Cmo/Cdo

* MEDIGENE AG: MEDIGENE APPOINTS DR. KAI PINKERNELL TO EXECUTIVE MANAGEMENT BOARD AS CMO/CDO Source text for Eikon: Further company coverage:

11 Apr 2018

BRIEF-Medigene AG Says ‍Planned 2018 EBITDA Loss Of EUR 21 - 23 Mln​

* PTA-NEWS: MEDIGENE AG: MEDIGENE PUBLISHES 2017 ANNUAL REPORT AND ANNOUNCES START OF CLINICAL TRIAL WITH TCR IMMUNOTHERAPY MDG1011

22 Mar 2018

BRIEF-Medigene Receives Approvals For First Clinical Trial With MDG1011

* SAYS RECEIVES APPROVALS FOR ITS FIRST CLINICAL TRIAL WITH TCR THERAPY MDG1011

21 Feb 2018

BRIEF-Medigene Strengthens Its Patent Portfolio With US Patent On Tagged TCR

* MEDIGENE STRENGTHENS ITS PATENT PORTFOLIO WITH A US PATENT ON A TAGGED TCR Source text for Eikon: Further company coverage: (Gdynia Newsroom)

01 Feb 2018

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS

11 Dec 2017

BRIEF-Medigene Sells US-Rights For Veregen, Raises 2017 Guidance

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017

05 Dec 2017

Earnings vs. Estimates